Revenue Insights: Pfizer Inc. and Amgen Inc. Performance Compared

Pfizer vs. Amgen: A Decade of Revenue Dynamics

__timestamp	Amgen Inc.	Pfizer Inc.
Wednesday, January 1, 2014	20063000000	49605000000
Thursday, January 1, 2015	21662000000	48851000000
Friday, January 1, 2016	22991000000	52824000000
Sunday, January 1, 2017	22849000000	52546000000
Monday, January 1, 2018	23747000000	53647000000
Tuesday, January 1, 2019	23362000000	51750000000
Wednesday, January 1, 2020	25424000000	41908000000
Friday, January 1, 2021	25979000000	81288000000
Saturday, January 1, 2022	26323000000	100330000000
Sunday, January 1, 2023	28190000000	58496000000

Unveiling the hidden dimensions of data

Revenue Growth: Pfizer Inc. vs. Amgen Inc.

In the ever-evolving pharmaceutical industry, revenue growth is a key indicator of a company's success. Over the past decade, Pfizer Inc. and Amgen Inc. have demonstrated contrasting revenue trajectories. From 2014 to 2023, Pfizer's revenue surged by approximately 100%, peaking in 2022 with a remarkable 70% increase from the previous year, largely driven by its COVID-19 vaccine sales. In contrast, Amgen's revenue grew steadily, with a 40% increase over the same period, reflecting its consistent innovation in biotechnology.

Key Insights

Pfizer's Revenue Spike: The year 2021 marked a turning point for Pfizer, with revenues jumping by 55% compared to 2020, showcasing its strategic market positioning.
Amgen's Steady Climb: Despite a slower growth rate, Amgen's revenue reached its highest in 2023, indicating resilience and adaptability in a competitive market.

These insights highlight the dynamic nature of the pharmaceutical sector and the diverse strategies employed by leading companies.

Published by

U.S. Securities and Exchange Commission

Source link

sec.gov

Date published

17 Jan 2025